-
P.
Helliwell,
J.
Firth,
G.
Ibrahim,
R.
Melsom,
I.
Shah,
D.
Turner
(2005)
Development of an assessment tool for dactylitis in patients with psoriatic arthritis.
The Journal of rheumatology, 32 9
-
P.
Healy,
P.
Helliwell
(2008)
Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
Arthritis and rheumatism, 59 5
-
C.
Leonardi,
R.
Matheson,
C.
Zachariae,
G.
Cameron,
Linda
Li,
E.
Edson-Heredia,
D.
Braun,
Subhashish
Banerjee
(2012)
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
The New England journal of medicine, 366 13
-
J.
Fries,
P.
Spitz,
R.
Kraines,
H.
Holman
(1980)
Measurement of patient outcome in arthritis.
Arthritis and rheumatism, 23 2
-
I.
McInnes,
P.
Mease,
B.
Kirkham,
A.
Kavanaugh,
C.
Ritchlin,
P.
Rahman,
D.
Heijde,
R.
Landewé,
P.
Conaghan,
A.
Gottlieb,
H.
Richards,
L.
Pricop,
G.
Ligozio,
M.
Patekar,
S.
Mpofu
(2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 386
-
A.
Lin,
Cory
Rubin,
R.
Khandpur,
J.
Wang,
Marybeth
Riblett,
S.
Yalavarthi,
Eneida
Villanueva,
P.
Shah,
M.
Kaplan,
A.
Bruce
(2011)
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
The Journal of Immunology, 187
-
S.
Weisman,
CR
Pollack,
RW
Gottschalk
(2003)
Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis
Journal of Dermatological Treatment, 14
-
G.
Wells,
J.
Becker,
J.
Teng,
M.
Dougados,
M.
Schiff,
J.
Smolen,
D.
Aletaha,
P.
Riel
(2008)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
Annals of the Rheumatic Diseases, 68
-
S.
Raychaudhuri
(2013)
Role of IL-17 in Psoriasis and Psoriatic Arthritis
Clinical Reviews in Allergy & Immunology, 44
-
S.
Kagami,
Heather
Rizzo,
J.
Lee,
Y.
Koguchi,
A.
Blauvelt
(2010)
Circulating Th17, Th22, and Th1 cells are increased in psoriasis.
The Journal of investigative dermatology, 130 5
-
D.
Heijde,
R.
Fleischmann,
J.
Wollenhaupt,
A.
Deodhar,
D.
Kielar,
F.
Woltering,
C.
Stach,
B.
Hoepken,
T.
Arledge,
P.
Mease
(2013)
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
Annals of the Rheumatic Diseases, 73
-
B.
Menon,
N.
Gullick,
G.
Walter,
Megha
Rajasekhar,
T.
Garrood,
H.
Evans,
L.
Taams,
B.
Kirkham
(2014)
Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
Arthritis & Rheumatology (Hoboken, N.j.), 66
-
D.
Gladman,
C.
Antoni,
P.
Mease,
D.
Clegg,
P.
Nash
(2005)
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Annals of the Rheumatic Diseases, 64
-
C.
Griffiths,
K.
Reich,
M.
Lebwohl,
P.
Kerkhof,
C.
Paul,
A.
Menter,
G.
Cameron,
J.
Erickson,
Lu
Zhang,
R.
Secrest,
S.
Ball,
D.
Braun,
O.
Osuntokun,
M.
Heffernan,
B.
Nickoloff,
K.
Papp
(2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
The Lancet, 386
-
P.
Healy,
P.
Helliwell
(2007)
Measuring dactylitis in clinical trials: which is the best instrument to use?
The Journal of rheumatology, 34 6
-
IR=inadequate responder; IXEQ2W=80 mg ixekizumab every 2 weeks
-
Toshiyuki
Yamamoto
(2013)
Angiogenic and Inflammatory Properties of Psoriatic Arthritis
ISRN Dermatology, 2013
-
C.
Jandus,
G.
Bioley,
J.
Rivals,
J.
Dudler,
D.
Speiser,
P.
Romero
(2008)
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.
Arthritis and rheumatism, 58 8
-
P.
Mease,
B.
WOOLLEY,
Brian
Wang,
D.
Globe,
Amitabh
Singh,
MS
Bitman
(2011)
Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction
The Journal of Rheumatology, 38
-
T.
Noordenbos,
N.
Yeremenko,
I.
Gofita,
M.
Sande,
P.
Tak,
J.
Cañete,
D.
Baeten
(2012)
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.
Arthritis and rheumatism, 64 1
-
Patients with presence of dactylitis at baseline b and baseline LDI-B score >0 (post-hoc analysis)
-
Supplementary Figure S2 Injection Schedule. Abbreviations: ADA=40 mg adalimumab every 2 weeks (active reference arm)
-
Downloaded from REFERENCES AND FURTHER READING
-
H.
Duncan,
D.
OberG,
W.
Eyler
(1965)
PSORIATIC ARTHRITIS.
Henry Ford Hospital medical bulletin, 13
-
K.
Bruynesteyn,
M.
Boers,
Piet
Kostense,
S.
Linden,
D.
Heijde
(2004)
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change
Annals of the Rheumatic Diseases, 64
-
D.
Heijde,
J.
Sharp,
S.
Wassenberg,
D.
Gladman
(2005)
Psoriatic arthritis imaging: a review of scoring methods
Annals of the Rheumatic Diseases, 64
-
Steven
Feldman,
Gerald
Krueger
(2005)
Psoriasis assessment tools in clinical trials
Annals of the Rheumatic Diseases, 64
-
Gladman
(2009)
Psoriatic arthritis
Dermatol Ther, 22
-
Ying-Ying
Leung,
L.
Tam,
E.
Kun,
E.
Li
(2007)
Psoriatic arthritis as a distinct disease entity.
Journal of postgraduate medicine, 53 1
-
M.
Chimenti,
E.
Ballanti,
C.
Perricone,
P.
Cipriani,
R.
Giacomelli,
R.
Perricone
(2013)
Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.
Autoimmunity reviews, 12 5
-
P.
Mease,
M.
Genovese,
M.
Greenwald,
C.
Ritchlin,
A.
Beaulieu,
A.
Deodhar,
R.
Newmark,
J.
Feng,
N.
Erondu,
A.
Nirula
(2014)
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
The New England journal of medicine, 370 24
-
J.
Fries,
P.
Spitz,
D.
Young
(1982)
The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.
The Journal of rheumatology, 9 5
-
E.
Leijten,
T.
Kempen,
M.
Boes,
J.
Amelsfort,
D.
Hijnen,
S.
Hartgring,
J.
Roon,
M.
Wenink,
T.
Radstake
(2015)
Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid
Arthritis & Rheumatology, 67
-
R.
Landewé,
V.
Strand,
D.
Heijde
(2013)
From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials
Annals of the Rheumatic Diseases, 72
-
A.
Kimball,
A.
Naegeli,
E.
Edson-Heredia,
C.‐Y.
Lin,
C.
Gaich,
E.
Nikaï,
K.
Wyrwich,
G.
Yosipovitch
(2016)
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis
British Journal of Dermatology, 175
-
P.
Mease,
I.
McInnes,
B.
Kirkham,
A.
Kavanaugh,
P.
Rahman,
D.
Heijde,
R.
Landewé,
P.
Nash,
L.
Pricop,
Jiacheng
Yuan,
H.
Richards,
S.
Mpofu
(2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
The New England journal of medicine, 373 14
-
K.
Vlam,
A.
Gottlieb,
P.
Mease
(2014)
Current concepts in psoriatic arthritis: pathogenesis and management.
Acta dermato-venereologica, 94 6
-
D.
Felson,
D.
Felson,
Jennifer
Anderson,
Jennifer
Anderson,
M.
Boers,
C.
Bombardier,
C.
Bombardier,
D.
Furst,
D.
Furst,
C.
Goldsmith,
C.
Goldsmith,
Linda
Katz,
Linda
Katz,
R.
Lightfoot,
R.
Lightfoot,
H.
Paulus,
H.
Paulus,
V.
Strand,
V.
Strand,
P.
Tugwell,
P.
Tugwell,
M.
Weinblatt,
M.
Weinblatt,
H.
Williams,
H.
Williams,
F.
Wolfe,
S.
Kieszak
(1995)
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.
Arthritis and rheumatism, 38 6
-
W.
Taylor,
D.
Gladman,
P.
Helliwell,
A.
Marchesoni,
P.
Mease,
H.
Mielants
(2006)
Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
Arthritis and rheumatism, 54 8
-
Weitao
Huang,
L.
Na,
P.
Fidel,
P.
Schwarzenberger
(2004)
Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice.
The Journal of infectious diseases, 190 3
-
IXEQ2W=80 mg ixekizumab every 2 weeks; IXEQ4W=80 mg ixekizumab every 4 weeks; PBO=placebo every 2 weeks; R=randomization
-
P.
Rich,
R.
Scher
(2003)
Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.
Journal of the American Academy of Dermatology, 49 2
